Connection

Michael Hallek to Antibodies, Neoplasm

This is a "connection" page, showing publications Michael Hallek has written about Antibodies, Neoplasm.
Connection Strength

0.124
  1. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.
    View in: PubMed
    Score: 0.098
  2. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.